methylprednisolone sodium succinate

P3, N=0, Withdrawn, The University of Queensland | N=224 --> 0 | Not yet recruiting --> Withdrawn

P1, N=35, Not yet recruiting, Baylor College of Medicine | Initiation date: Oct 2025 --> Jan 2026

P=N/A, N=30, Recruiting, Assiut University | Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2025 --> Dec 2025

P4, N=220, Not yet recruiting, Sunnybrook Health Sciences Centre

P3, N=90, Recruiting, Centre Hospitalier Universitaire de Saint Etienne | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2027

Symptoms resolved following the administration of intravenous methylprednisolone (0.5 mg/kg) and maleate pheniramine (45.5 mg/mL). The patient continued abemaciclib at 300 mg/day without recurrence of symptoms. This case highlights the importance of drug desensitization in oncology, particularly in patients for whom no alternative therapies are available.

Initial treatment with high-dose methylprednisolone and intravenous immunoglobulin showed limited improvement. The mechanism may involve its ability to inhibit macrophage proliferation and promote anti-inflammatory effects. Further prospective studies are needed to validate the role of cyclophosphamide in managing T-DXd-related ILD and to explore risk stratification for optimal toxicity management.

P3, N=271, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Feb 2028 --> Feb 2031

P=N/A, N=100, Not yet recruiting, Shengli Oilfield Central Hospital; Shengli Oilfield Central Hospital

P1/2, N=55, Recruiting, Masonic Cancer Center, University of Minnesota | Trial primary completion date: Sep 2025 --> Sep 2026

We report a 74-year-old woman who initially presented with a 2-month history of an erythematous rash over the right greater trochanter, unresponsive to oral flucloxacillin...She received intravenous methylprednisolone followed by intravenous immunoglobulins, but her condition deteriorated, and she died shortly thereafter...Anti-MDA5 dermatomyositis is an important differential in patients with new onset interstitial lung disease, pneumomediastinum, and pneumopericardium due to its rapidly progressive nature. Thorough history and examination for skin manifestations of anti-MDA5 dermatomyositis is crucial so that a diagnosis can be made promptly and treatment started at the earliest opportunity to avoid development of fatal disease-related complications and mortality.

Despite aggressive interventions-high-dose methylprednisolone, intravenous immunoglobulin, plasma exchange, and ruxolitinib combined with intrathecal therapy-the patient remained comatose and succumbed to multi-organ failure. Furthermore, this report highlights the urgent need for optimized early diagnostic strategies and targeted therapeutic approaches for CNS-HLH. The case provides critical insights into the clinical management and mechanistic understanding of post-transplant HLH.